The authors concluded that Pembrolizumab alone is an appropriate first-line treatment for PD-L1 positive recurrent or metastatic HNSCC, and the association between Pembrolizumab and chemotherapy is an appropriate first-line treatment for recurrent or metastatic HNSCC [10]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.